Compare · MDLN vs SGHT
MDLN vs SGHT
Side-by-side comparison of Medline Inc. (MDLN) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 99.2x SGHT ($484.8M).
- Both names hit the wire about 7 times in the past 4 weeks.
- MDLN has more recent analyst coverage (25 ratings vs 21 for SGHT).
- Company
- Medline Inc.
- Sight Sciences Inc.
- Price
- -
- -
- Market cap
- $48.08B
- $484.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 7
- 7
- Recent ratings
- 25
- 21
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest SGHT
- H.C. Wainwright initiated coverage on Sight Sciences with a new price target
- SEC Form 4 filed by Sight Sciences Inc.
- SEC Form 4 filed by Sight Sciences Inc.
- SEC Form 4 filed by Sight Sciences Inc.
- SEC Form 4 filed by Sight Sciences Inc.
- SEC Form 4 filed by Sight Sciences Inc.
- Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
- Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
- TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
- Chief Legal Officer Rashid Kashif was granted 181,818 shares (SEC Form 4)